p53 activates either survival or apoptotic signaling responses in Lupulone-Treated human colon adenocarcinoma cells and derived metastatic cells

Translational Oncology

Volumn 3, Issue 5, 2010, Pages 286-292

  Lamy, Virginie ^a,b   Bousserouel, Souad ^a,b   Gossé, Francine ^a,b   Minker, Carole ^a   Lobstein, Annelise ^a   Raul, Francis ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b IRCAD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LUPULON; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOPLASM; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MITOCHONDRIAL MEMBRANE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 78449248936     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10124     Document Type: Article

References (31)

1. Meek DW (1999). Mechanisms of switching on p53: a role for covalent modification. Oncogene 18, 7666-7675.
2. Laptenko O and Prives C (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13, 951-961.
3. Fuster JJ, Sanz-González SM, Moll UM, and Andrés V (2007). Classic and novelroles of p53: prospects for anticancer therapy. TREND Mol Med 13, 192-199.
4. Wolff S, Erster S, Palacios G, and Moll UM (2008). p53's mitochondrial translocationand MOMP action is independent of Puma and Bax and severely disruptsmitochondrial membrane integrity. Cell Res 18, 733-744.
5. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, and Stetler-Stevenson WG (2000). Validation of a model of colon cancer progression. J Pathol 192, 446-454.
6. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, and Livingston EH (2007). Modification of gene productsinvolved in resistance to apoptosis in metastatic colon cancer cells: role of Fas, Apaf-1, NF-κB, IAPs, Smac/DIABLO and AIF. J Surg Res 142, 184-194.
7. Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, and Ohashi M (1999). Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 19, 3099-3108.
8. Rochette PJ, Bastien N, Lavoie J, Guérin SL, and Drouin R (2005). SW480, ap53 double-mutant cell line retains proficiency for some p53 functions. J Mol Biol 352, 44-57.
9. Lamy V, Roussi S, Chaabi M, Gosse F, Lobstein A, and Raul F (2008). Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAILreceptors, in human colon tumor cells and in their derived metastatic cells. Apoptosis 13, 1232-1242.
10. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, and Moll UM (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11,577-590.
11. Sayan BS, Sayan E, Knight RA, Melino G, and Cohen GM (2006). p53 is cleavedby caspases generating fragments localizing to mitochondria. J Biol Chem 281,13566-13573.
12. Lamy V, Roussi S, Chaabi M, Gossé F, Schall N, Lobstein A, and Raul F (2007). Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis 28, 1575-1581.
13. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression datausing real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408.
14. Roy AM, Baliga MS, Elmets CA, and Katiyar SK (2005). Grape seed proanthocyanidinsinduce apoptosis through p53, Bax and caspase-3 pathways. Neoplasia 7, 24-36.
15. Liu HF, Hsiao PW, and Chao JI (2008). Celexomib induces p53-PUMA pathwayfor apoptosis in human colorectal cancer cells. Chem Biol Interact 176, 48-57.
16. Komarova EA and Gudkov AV (2000). Suppression of p53: a new approach toovercome side effects of antitumor therapy. Biochemistry (Mosc) 65, 41-48.
17. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, and Mattson MP (2001). A synthetic inhibitor of p53 protects neurons against deathinduced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 77, 220-228.
18. Li X, Ding X, and Adrian TE (2004). Arsenic trioxide causes redistribution ofcell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 22, 389-400.
19. Riccardi C and Nicoletti I (2006). Analysis of apoptosis by propidium iodidestaining and flow cytometry. Nat Protoc 1, 1458-1461.
20. Charlot JF, Nicolier M, Prétet JL, and Mougin C (2006). Modulation of p53transcriptional activity by PRIMA-1 and pifithrin-α on staurosporine-inducedapoptosis of wild-type and mutated p53 epithelial cells. Apoptosis 11, 813-827.
21. Amundson SA, Myers TG, and Fornace AJ Jr (1998). Roles for p53 in growtharrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17,3287-3299.
22. Shi J and Shen HM (2008). Critical role of Bid and Bax in indirubin-3′-monoxime-induced apoptosis in human cancer cells. Biochem Pharmacol 75, 1729-1742.
23. Hainaut P and Vähäkangas K (1997). p53 as a sensor of carcinogenic exposures:mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol 45, 833-844.
24. Vazquez A, Bond EE, Levine AJ, and Bond GL (2008). The genetics of the p53pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7, 979-987.
25. Hirota Y, Horiuchi T, and Akahane K (1996). p53 antisense oligonucleotide inhibitsgrowth of human colon tumor and normal cell lines. Jpn J Cancer Res 87,735-742.
26. Dumaz N and Meek DW (1999). Serine 15 phosphorylation stimulates p53transactivation but does not directly influence interaction with HDM2. EMBO J 18, 7002-7010.
27. Zhang Y and Xiong Y (2001). A p53 amino-terminal nuclear export signal inhibitedby DNA damage-induced phosphorylation. Science 292, 1910-1915.
28. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, and Mattson MP (2001). A synthetic inhibitor of p53 protects neuron against deathinduced by ischemic and excitotoxic insults and amyloid α-peptide. J Neurochem 77, 220-228.
29. Komarova EA and Gudkov AV (2000). Suppression of p53: a new approach toovercome side effects of antitumor therapy. Biochemistry (Mosc) 65, 41-48.
30. Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, Banerjee S, Choudhuri T, Mandal D, Bhattacharyya A, Sa G, et al. (2008). Contribution ofp53-mediated Bax transactivation in theaflavin-induced mammary epithelialcarcinoma cell apoptosis. Apoptosis 13, 771-781.
31. Kelly KJ, Plotkin Z, Vulgamott SL, and Dagher PC (2003). P53 mediates theapoptotic response to GTP depletion after renal ischemia-reperfusion: protectiverole of a p53 inhibitor. J Am Soc Nephrol 14, 265-267.